You are here: Industry Insights > FDA

News List

FDA Approves Component of Treatment Regimen for Most Common Childhood Cancer fda.gov
July 02, 2021
Today, the U.S. Food and Drug Administration approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients.
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines prnasia
July 01, 2021
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, announced that it has raised $73M in Series B financing.
Lupin gets tentative US FDA nod for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) tablets under PEPFAR expresspharma
July 01, 2021
TLD is recommended by WHO, USAID and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg.
Axio Biosolutions gets USFDA clearance for Axiostat Patch for vascular bleeding control expresspharma
July 01, 2021
Axio Biosolutions, an integrated wound care company has announced FDA 510(k) clearance of its hemostatic product Axiostat Patch, which helps control moderate to severe bleeding in vascular procedures, surgical debridement sites, puncture sites and more.
CBD Products Gain Following Among Fibromyalgia Patients drugs
July 01, 2021
Could the answer to easing the tough-to-treat chronic pain and fatigue of fibromyalgia be found in edibles and other products containing CBD?
Apellis, Beam ink base-editing pact to tackle complement-driven diseases firstwordpharma
July 01, 2021
Apellis Pharmaceuticals and Beam Therapeutics have forged a five-year research partnership that will apply the latter's base-editing platform toward discovering new treatments for complement-driven diseases, the companies announced Wednesday.
Freeline Announces Executive Leadership Changes firstwordpharma
July 01, 2021
FRLN today announced the expansion of its executive leadership team with the appointment of James "Jay" Bircher as Chief Technical Operations Officer effective July 1, 2021.
FDA Approves Soaanz (torsemide) for Edema Treatment in Patients with Heart Failure and Renal Disease drugs
June 30, 2021
Sarfez Pharmaceuticals announced today approval by the U.S. Food and Drug Administration (FDA) of the Virginia-based company’s New Drug Application for Soaanz, a once-a-day improved formulation of the loop diuretic torsemide.
Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for Pedmark drugs
June 30, 2021
Fennec Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the resubmission of its New Drug Application (NDA) for Pedmark.
Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children drugs
June 29, 2021
Genentech announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults and pediatric patients

Previous page 1 2 3 4 5 6 7 8 9 10 ... 366 367 Next page